A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2018
At a glance
- Drugs SHP 647 (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms FIGARO UC 302
- Sponsors Shire
- 19 Jul 2018 Planned End Date changed from 29 Nov 2020 to 9 Aug 2020.
- 19 Jul 2018 Planned primary completion date changed from 29 Nov 2020 to 9 Aug 2020.
- 11 Dec 2017 Status changed from not yet recruiting to recruiting.